Article

2002: research confirms benefit of IOP-lowering treatment

Publication of results from the Ocular Hypertension Treatment Study (OHTS) and the Early Manifest Glaucoma Trial (EMGT) represents two of the most notable events occurring in the field of glaucoma in 2002, but the year is also marked by a number of other significant developments with the potential to influence patient evaluation and management.

Related Videos
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
Related Content
Researchers offer insights into wet AMD: Study reveals potential to enhance anti-VEGF therapy with experimental drug to preserve vision
November 8th 2024

Researchers offer insights into wet AMD: Study reveals potential to enhance anti-VEGF therapy with experimental drug to preserve vision

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

Formosa Pharmaceuticals announces top-line results from Chinese trial evaluating APP13007
November 6th 2024

Formosa Pharmaceuticals announces top-line results from Chinese trial evaluating APP13007

EyePod podcast: Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)
November 1st 2024

Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)

LumiThera’s Valeda Light Delivery System receives marketing authorization from FDA
November 6th 2024

LumiThera’s Valeda Light Delivery System receives marketing authorization from FDA

Study: Aromatherapy decreased postoperative patient anxiety and pain associated with oculoplastic surgery
November 6th 2024

Study: Aromatherapy decreased postoperative patient anxiety and pain associated with oculoplastic surgery

© 2024 MJH Life Sciences

All rights reserved.